InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU – Get Free Report)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $10.82. InfuSystem shares last traded at $10.55, with a volume of 225,404 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on InfuSystem in a research report on Wednesday, August 23rd. They issued a “buy” rating for the company.
InfuSystem Stock Performance
InfuSystem (NYSEAMERICAN:INFU – Get Free Report) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $31.74 million during the quarter. InfuSystem had a return on equity of 1.36% and a net margin of 0.56%.
Insider Buying and Selling at InfuSystem
In other news, Director R. Rimmy Malhotra sold 10,000 shares of the stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $10.73, for a total transaction of $107,300.00. Following the completion of the sale, the director now directly owns 160,416 shares in the company, valued at $1,721,263.68. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 82,356 shares of company stock worth $864,215 over the last three months. Company insiders own 18.50% of the company’s stock.
Institutional Investors Weigh In On InfuSystem
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its position in InfuSystem by 597.8% during the 2nd quarter. BlackRock Inc. now owns 1,029,364 shares of the medical instruments supplier’s stock valued at $9,913,000 after buying an additional 881,856 shares in the last quarter. Meros Investment Management LP raised its holdings in InfuSystem by 7.1% in the second quarter. Meros Investment Management LP now owns 885,945 shares of the medical instruments supplier’s stock worth $8,532,000 after buying an additional 58,904 shares during the last quarter. Wasatch Advisors Inc. increased its position in shares of InfuSystem by 18.6% during the first quarter. Wasatch Advisors Inc. now owns 859,679 shares of the medical instruments supplier’s stock valued at $8,425,000 after acquiring an additional 135,076 shares in the last quarter. Vanguard Group Inc. raised its holdings in InfuSystem by 8.6% in the 1st quarter. Vanguard Group Inc. now owns 859,052 shares of the medical instruments supplier’s stock worth $8,418,000 after acquiring an additional 68,242 shares during the last quarter. Finally, Punch & Associates Investment Management Inc. lifted its position in InfuSystem by 16.0% in the 1st quarter. Punch & Associates Investment Management Inc. now owns 785,245 shares of the medical instruments supplier’s stock valued at $6,086,000 after acquiring an additional 108,454 shares in the last quarter. 65.03% of the stock is currently owned by institutional investors.
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
- Five stocks we like better than InfuSystem
- Stock Splits, Do They Really Impact Investors?
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- What Does a Stock Split Mean?
- MarketBeat Week in Review – 9/11 – 9/15
- How to Invest in Biotech Stocks
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.